In the rapidly evolving field of genomics, a new class of non-coding RNAs has captured the attention of researchers worldwide - circular RNAs (circRNAs). Unlike their linear counterparts, circRNAs are characterized by a unique covalently closed loop structure, making them highly stable and resistant to exonuclease digestion. This remarkable feature has sparked a surge of interest in understanding the biogenesis, function, and potential clinical applications of these enigmatic molecules.
Recognizing the growing importance of circRNA research, CD Genomics, a leading provider of next-generation sequencing services, is proud to announce the launch of its comprehensive CircRNA Sequencing service. Leveraging the latest Illumina platforms, this service offers researchers a fast, economical, and highly accurate approach to characterizing circRNAs from various biological samples.
"CircRNAs have emerged as a fascinating new frontier in the world of non-coding RNAs, with the potential to revolutionize our understanding of gene expression regulation and disease pathogenesis," said the Chief Scientific Officer at CD Genomics. "Our CircRNA Sequencing service is designed to empower researchers, enabling them to uncover the hidden secrets of these unique RNA species and unlock new avenues for biomarker discovery and therapeutic development."
Unlike traditional methods that rely on microarray technology, CD Genomics' CircRNA Sequencing service harnesses the power of high-throughput RNA sequencing. This approach offers several key advantages, including detecting novel circRNAs, quantifying their expression across a broader dynamic range, and achieving enhanced sensitivity and specificity compared to microarray-based techniques.
The CircRNA Sequencing workflow at CD Genomics is meticulously designed to ensure the highest quality and reliability of the data. It begins with the depletion of ribosomal RNA, followed by linear RNA digestion and strand-specific library preparation. This comprehensive process, executed by a team of experienced scientists, ensures that the resulting data accurately reflects the circRNA landscape within the sample.
"The identification and characterization of circRNAs hold immense promise for advancing our understanding of various disease states, from cancer to neurological disorders," explained the scientist. "Our CircRNA Sequencing service provides researchers with the tools they need to unravel the complex regulatory networks governed by these enigmatic molecules, paving the way for the development of novel biomarkers and therapeutic interventions."
With its commitment to cutting-edge technology and scientific expertise, CD Genomics is poised to be a driving force in the burgeoning field of circRNA research. By offering this innovative CircRNA Sequencing service, the company aims to empower researchers worldwide to explore the untapped potential of this novel class of non-coding RNAs and unlock new frontiers in the pursuit of scientific discovery.
About CD Genomics
CD Genomics is a leading provider of comprehensive genomic services, specializing in cutting-edge technologies such as CircRNA sequencing. With state-of-the-art sequencing platforms and a team of bioinformatics experts, the company offers a wide range of services to support researchers and clinicians in their quest for groundbreaking discoveries.
Contact
Address: Shirley, NY 11967, USA
Email: contact@cd-genomics.com
Comments
0 comment